Alexander M. Lesokhin, MD, assistant attending, Department of Medicine and Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses some of the exciting advancements currently happening in the field of multiple myeloma.
According to Lesokhin, a lot of the excitement is around chimeric antigen receptor (CAR) T-cells, though they are not FDA approved yet. Data has shown significant initial responses with these therapies, but there is still time to see how durable the responses are.
Antibody drug conjugates are also being researched right now. The BCMA conjugate in particular has shown efficacy in patients with myeloma who are refractory in every other line of therapy. There was a 60% response rate in that patient population with manageable toxicities, Lesokhin says.
This was originally published on OncLive